TIM‐3 deficiency presenting with two clonally unrelated episodes of mesenteric and subcutaneous panniculitis‐like T‐cell lymphoma and hemophagocytic lymphohistiocytosis
Abstract: This report offers novel clinical and diagnostic aspects of the association between germline mutations in HAVCR2 and subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL). The patient presented with panniculitis‐like T‐cell lymphoma involving mesenteric fatty tissue associated with hemophagocytic lymphohistiocytosis (HLH). Five years later, he developed a clonally unrelated SPTCL and underwent hematopoietic stem cell transplantation. Retrospectively, he was found to carry germline mutations in HAVCR2 associated with reduced T‐cell immunoglobulin mucin‐3 (TIM‐3) expression. We show that mesenteric fatty tissue localization of SPTCL can be the presenting manifestation of TIM‐3 deficiency, that this condition predisposes to recurrent lymphoma, and that flow cytometry is a possible screening tool
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Pediatric blood & cancer. - 67, 6 (2020) , e28302, ISSN: 1545-5017
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2020
- Urheber
- DOI
-
10.1002/pbc.28302
- URN
-
urn:nbn:de:bsz:25-freidok-1658993
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
Entstanden
- 2020
Ähnliche Objekte (12)
Disease pathophysiology in murine models of primary hemophagocytic lymphohistiocytosis: triggers and effectors
Cell versus cytokine – directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity
Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
The microbiome modifies manifestations of hemophagocytic lymphohistiocytosis in perforin‐deficient mice
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Disease pathophysiology in murine models of primary hemophagocytic lymphohistiocytosis: triggers and effectors
Cell versus cytokine – directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity
Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
The microbiome modifies manifestations of hemophagocytic lymphohistiocytosis in perforin‐deficient mice
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Disease pathophysiology in murine models of primary hemophagocytic lymphohistiocytosis: triggers and effectors
Cell versus cytokine – directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity
Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
The microbiome modifies manifestations of hemophagocytic lymphohistiocytosis in perforin‐deficient mice
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox